HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published All Versions of this Article: ERC-08-0229v1 16/1/255    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Kauhanen, S. Articles by Nuutila, P. Search for Related Content PubMed PubMed Citation Articles by Kauhanen, S. Articles by Nuutila, P.

¹ Turku PET Center, Turku University Central Hospital, PO Box 52, FIN-20521 Turku, Finland² Department of Surgery, Turku University Central Hospital, Turku, Finland³ Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland⁴ Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland⁵ Department of Medicine, Satakunta Central Hospital, Pori, Finland⁶ Department of Medicine, Oulu University Central Hospital, Oulu, Finland⁷ Central Hospital of Middle Finland, Jyväskylä, Finland⁸ Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland⁹ Department of Medicine, Turku University Central Hospital, Turku, Finland

(Correspondence should be addressed to P Nuutila; Email: pirjo.nuutila{at}tyks.fi)

The study was set up to determine the clinical value of dihydroxyphenylalanine positron emission tomography-computed tomography ([¹⁸F]DOPA PET-CT) in patients with neuroendocrine tumors (NETs). Eighty-two patients with suspected/known NET were imaged with PET(-CT) using [¹⁸F]DOPA. Patients were divided into two groups: primary diagnosis/staging and restaging of disease. All patients without previous diagnosis of NET had biochemical proof of disease. The diagnostic accuracy of PET was assessed by comparing the histopathology and clinical follow-up. The overall accuracy of [¹⁸F]DOPA PET was 90%. In patients having PET for primary diagnosis/staging (n=32), the accuracy of PET was 88%, and for restaging 92% (n=61). The mean S.D. sizes of primary and metastatic lesions detected by PET were 26±11 and 16±9 mm respectively. In organ-region-specific analysis, the sensitivity and specificity were 100% in the primary diagnosis of pheochromocytoma (n=16) and metastases were found in all cases with recurrent disease (n=5). The accuracy for NET of gastrointestinal tract was 92% in restaging (n=24). For the NETs located in the head–neck–thoracic region (n=19), the overall accuracy of PET was 89% including 12 cases of recurrent medullary thyroid cancer with a sensitivity of 90%. In analysis of patients with biochemical proof of disease combined with negative conventional imaging methods, PET had positive and negative predictive value of 92% and 95% respectively. [¹⁸F]DOPA PET-CT provided important additional information in the diagnosis of pheochromocytoma and restaging of known NET. Both in primary diagnosis and in patients with formerly known NET and increasing tumor markers, [¹⁸F]DOPA PET-CT is a sensitive first-line imaging method.

This article has been cited by other articles:

				H. Minn, S. Kauhanen, M. Seppanen, and P. Nuutila 18F-FDOPA: A Multiple-Target Molecule J. Nucl. Med., December 1, 2009; 50(12): 1915 - 1918. [Abstract] [Full Text] [PDF]